4.7 Review

The Cytokine Flt3-Ligand in Normal and Malignant Hematopoiesis

Journal

Publisher

MDPI
DOI: 10.3390/ijms18061115

Keywords

Flt3; hematopoiesis; acute myeloid leukemia (AML); cytokines; Flt3 with internal tandem duplications (FLT3-ITD)

Funding

  1. European Union [315902]
  2. Swiss National Science Foundation
  3. Novartis Foundation for Medical and Biological Research

Ask authors/readers for more resources

The cytokine Fms-like tyrosine kinase 3 ligand (FL) is an important regulator of hematopoiesis. Its receptor, Flt3, is expressed on myeloid, lymphoid and dendritic cell progenitors and is considered an important growth and differentiation factor for several hematopoietic lineages. Activating mutations of Flt3 are frequently found in acute myeloid leukemia (AML) patients and associated with a poor clinical prognosis. In the present review we provide an overview of our current knowledge on the role of FL in the generation of blood cell lineages. We examine recent studies on Flt3 expression by hematopoietic stem cells and its potential instructive action at early stages of hematopoiesis. In addition, we review current findings on the role of mutated FLT3 in leukemia and the development of FLT3 inhibitors for therapeutic use to treat AML. The importance of mouse models in elucidating the role of Flt3-ligand in normal and malignant hematopoiesis is discussed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available